MLYS$16.181.19%0.19
After Hours: 16.25+0.07 +0.43%
Mineralys Therapeutics Inc (MLYS)
Date: 2026-11-04 16:00O: 16.41H: 17.02L: 15.53C: 17.00Vol: 1.926M
Mineralys Therapeutics Inc stock is traded at $16.18, with a volume of 397,988. It is up +1.19% in the last 24 hours and down -31.53% over the past month. Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Previous Close:
$15.99
Open:
$16.41
24h Volume:
397,988
Relative Volume:
0.18
Market Cap:
$1.43B
Revenue:
-
Net Income/Loss:
-$151.78M
P/E Ratio:
-
EPS:
-$2.06
Net Cash Flow:
-$136.42M
1W Performance:
-24.32%
1M Performance:
-31.53%
6M Performance:
-45.43%
1Y Performance:
-59.36%
1-Day Range:
$15.53$16.47
1-Week Range:
$15.33$22.48
52-Week Range:
$15.33$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(888) 378-6240Address
150 N. RADNOR CHESTER RD., RADNOR, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Mineralys Therapeutics Inc Stock (MLYS) Insider Trading
- Rodman David MalcomOct 13 '26Officer
- Transaction
- Proposed Sale
- Cost
- $22.04
- #Shares
- 3,542
- Value ($)
- 78,066
- #Shares Total
- 0
- Congleton JonSep 30 '26Chief Executive Officer
- Transaction
- Sale
- Cost
- $25.46
- #Shares
- 75,000
- Value ($)
- 1,909,665
- #Shares Total
- 528,621
- Congleton JonSep 30 '26Officer
- Transaction
- Proposed Sale
- Cost
- $25.46
- #Shares
- 75,000
- Value ($)
- 1,909,662
- #Shares Total
- 0
- CATALYS PACIFIC FUND LPSep 22 '26Director
- Transaction
- Proposed Sale
- Cost
- $28.81
- #Shares
- 104,320
- Value ($)
- 3,005,303
- #Shares Total
- 0
- Slingsby Brian TaylorSep 22 '26Director
- Transaction
- Sale
- Cost
- $28.81
- #Shares
- 104,320
- Value ($)
- 3,005,303
- #Shares Total
- 7,805,718
- Warren EricSep 21 '26Chief Commercial Officer
- Transaction
- Sale
- Cost
- $28.12
- #Shares
- 7,438
- Value ($)
- 209,136
- #Shares Total
- 38,400
- Warren EricSep 21 '26Officer
- Transaction
- Proposed Sale
- Cost
- $28.12
- #Shares
- 7,438
- Value ($)
- 209,135
- #Shares Total
- 0
- Warren EricSep 21 '26Chief Commercial Officer
- Transaction
- Option Exercise
- Cost
- $13.24
- #Shares
- 7,438
- Value ($)
- 98,479
- #Shares Total
- 45,838
- Rodman David MalcomSep 17 '26Officer
- Transaction
- Proposed Sale
- Cost
- $27.95
- #Shares
- 417
- Value ($)
- 11,655
- #Shares Total
- 0
- Karydas DaphneSep 15 '26Officer
- Transaction
- Proposed Sale
- Cost
- $28.58
- #Shares
- 3,000
- Value ($)
- 85,740
- #Shares Total
- 0
